The EU-regulation on medicinal products for paediatric use: Impacts on child and adolescent psychiatry and clinical research with minors

European Child and Adolescent Psychiatry

Volumn 16, Issue 4, 2007, Pages 229-235

  Kölch, Michael ^a   Schnoor, Kathlen ^a   Fegert, Jörg M ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

EU regulation; Medicines; Paediatrics; Psychopharmacological interventions; Research

Indexed keywords

ARTICLE; CHILD PSYCHIATRY; FUNDING; HEALTH CARE; HEALTH CARE POLICY; HUMAN; MEDICAL RESEARCH; MENTAL DISEASE;

ADOLESCENT; ADOLESCENT PSYCHIATRY; ADVISORY COMMITTEES; BIOMEDICAL RESEARCH; CHILD; CHILD PSYCHIATRY; CLINICAL TRIALS; CROSS-CULTURAL COMPARISON; DELIVERY OF HEALTH CARE; DRUG AND NARCOTIC CONTROL; EUROPEAN UNION; HUMANS; LEGISLATION, DRUG; MENTAL DISORDERS; MINORS; RESEARCH SUPPORT; UNITED STATES;

EID: 34250362357     PISSN: 10188827     EISSN: 1435165X     Source Type: Journal    
DOI: 10.1007/s00787-006-0594-8     Document Type: Article

References (30)

1. Baber NS (2005) Tripartite meeting. Paediatric regulatory guidelines: do they help in optimizing dose selection for children? Brit J Clin Pharmacol 59:6660-6662
2. Bodenheimer T (2000) Uneasy alliance-clinical investigators and the pharmaceutical industry. N Engl J Med 342(20):1539-1544
3. Bücheler R, Schwab M, Mörike K, Kalchthaler B, Mohr H, Schröder H, Schwoerer P, Gleiter CH (2002) Off-label prescribing to outpatient children. Brit Med J 324:1311-1312
4. Commission of the European Communities (2004) Proposal for a Regulation of the European Parliament and the Council on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/83/EC and Regulation (EC) No 726/2004 (presented by the Commission) {SEC(2004) 1144} COM(2004) 599 final 2004/0217 (COD), Brussels, 29.9.2004
5. Commission of the European Communities (2005) Amended proposal for a Regulation of the European Parliament and the Council on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/83/EC and Regulation (EC) No 726/2004 (presented by the Commission pursuant to Article 250 (2) of the EC Treaty), COM(2005) 577 final, 2004/0217 (COD), Brussels, 10.11.2005
6. Commission of the European Communities (2006) Communication from the Commission to the European Parliament pursuant to the second subparagraph of Article 251 (2) of the EC Treaty concerning the common position of the Council with a view to the adoption of a regulation on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004, COM(2006) 118 final, 2004/0217(COD), Brussels, 13.3.2006
7. Conroy S, Choonara I, et al. (2000) Survey of unlicensed and off label drug use in paediatric wards in European countries. European network for drug investigation in children. Brit Med J 320(7227):79-82
8. EMEA (2006) Paediatric Working Party (PEG) Work programme for 2006, EMEA/CHMP/406990/2005, http://www.emea.eu.int/pdfs/human/peg/40699005en.pdf (access verified 22 June 2006)
9. Entorf H, Fegert JM, et al. (2004) Children in need of medical innovation, ZEW Zentrum für Europäische Wirtschaftsforschung GmbH:28
10. European Commission (2001) Directive 2001/20/EC Official Journal of the European Communities L 121/34
11. Fegert JM, Kölch M, et al. (2003) Sichere und wirksame Arzneimittel auch für Kinder. Z Rechtspol 36(12):446-450
12. Food and Drug Administration (2003): Approved moieties to which FDA has granted pediatric exclusivity for pediatric studies under section 505A of the Federal Food, Drug and Cosmetic Act. Available at: http://www.fda.gov/cder/ pediatric/exgrant.htm, accessed July 19, 2006
13. Grieve J, Tordoff J, Reith D, Norris P (2005) Effect of the pediatric exclusivity provision on children's access to medicines. Brit J Clin Pharmacol 59:(6) 730-735
14. Ian CK, Wong FMCB, Paramala JS, Macey LM (2004) Use of selective serotonin reuptake inhibitors in children and adolescents. Drug Safety 27(13):991-1000
15. Insel T, Nakamura (2006) The value and limitations of large practical clinical trials in informing practice: The NIMH Perspective; Program from 46th Annual Meeting NCDEU, Boca
16. Klein DF (2006) The flawed basis for FDA post-marketing safety decisions: the example of antidepressants and children. Neuropsychopharmacology 31:689-699
17. Knöppel C, Klinger O, Soergel M, Seyberth HW, Leonhardt A (2000) Anwendung von Medikamenten außerhalb der Zulassung oder ohne Zulassung bei Kindern. Monatschr Kinderheilkd 148:904-908
18. Kölch M, Lippert HD, Fegert JM (2006). Die Auswirkungen der 12. und der 14. Novelle zum AMG auf die Forschung mit Arzneimitteln für Kinder. Eine Übersicht zu den Neuregelungen, Zeitschrift für Kinder- und Jugendpsychiatrie. Z Kinder Jugendpsychiatr 34(2):117-126
19. Lieberman JA, Stroup TS, et al. (2005) Effectiveness of antipsychotic drugs in patients with schizophrenia (CATIE-study). N Engl J Med 353(12):1209-1223
20. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J; Treatment for Adolescents With Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. : JAMA. 2004 Aug 18;292(7):807-820
21. MTA Cooperative Group (1999) A 14-month randomized clinical trial of treatment strategies for attention deficit/hyperactive disorder. Arch Gen Psychiatry 56, 1073-1086
22. Rose K (2005) Better medicines for children- where are we and where do we want to be? Brit J Clin Pharmacol 06/2005 59(6):657
23. Schubert Silvia, Lippert Hans-Dieter, Fegert Jörg M, Kölch Michael (2006) Industrieunabhängige Forschung an Kindern und die 12. Novelle des Arzneimittelgesetzes Eine Studie zum Vergleich klinischer Prüfungen vor und nach der 12. Novelle des Arzneimittelgesetzes ( = A comparison of industry sponsored and investigator initiated trials in children before and after the 12th amendment of German drug law) Monatschrift Kinderheilkunde (in press)
24. Seyberth HW (2006) Zukünftige Anforderungen aus pädiatrischer Sicht ( = future requirements on the Regulation - the point of view of paediatrics lecture workshop European Regulation on medicinal products for paediatric use in Germany, impacts on paediatrics in Germany, 25.04.2006, Mainz
25. Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, Harding M, Faraone SV, Seidman L (1998) Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155:S693-S695
26. Sudhop T (2006) Voraussetzungen und Durchführung pädiatrischer klinischer Prüfungen aus Sicht einer Bundesoberbehörde ( = Prerequisities and conduct of clinical trials - the point of view of a regulation authority), lecture workshop European Regulation on medicinal products for paediatric use in Germany, impacts on paediatrics in Germany, 25.04.2006, Mainz
27. Tan J, Fegert JM (2004) Capacity and competence in child and adolescent psychiatry. Health Care Anal 12(4):285-294
28. Vitiello B, Heiligenstein JH, et al. (2004) The interface between publicly funded and industry-funded research in pediatric psychopharmacology: opportunities for integration and collaboration. Biol Psychiatry 56:3-9
29. Werner E. (2006) Europäische Kinderarzneimittelverordnung ( = European Regulation on medicinal products for paediatric use), lecture workshop European Regulation on medicinal products for paediatric use in Germany, impacts on paediatrics in Germany, 25.04.2006, Mainz
30. Zito JM, Derivan AT, Greenhill L (2004) Making research data available: an ethical imperative demonstrated by the SSRI debacle. J Am Acad Child Adoles Psychiatry 43(5):512-514